Prof Mike M. Chirenje (MD, FRCOG) – Vice Chair

MC

Mike Z. Chirenje is a Professor and attending Gynaecological Oncologist at the University of Zimbabwe in Harare. He has been the Director of UZ dysplasia clinic in Harare Spilhaus clinic for  the past 25 years, which introduced digital colposcopy, loop excision treatment, cryotherapy treatment,  for all women research participants and referrals from 13 urban primary care clinics.

He teaches fourth and final year medical students and residents in Obstetrics and Gynaecology clinical skills including operative gynaecological cancer cases.

Prof ZM Chirenje was the Principal investigator of a landmark study on the screening of cervical cancer which enrolled 11,000 women in Harare, and was published in the British Lancet in 1999. The study demonstrated the effectiveness of Visual Inspection with Acetic Acid (VIA) in resource limited settings. VIA is now a standard screening test for cervical cancer in many African countries including Zimbabwe, and other low resource countries in South America and South East Asia..

Prof ZM Chirenje Chirenje has also  been  the Executive Director  of  UZ-UCSF Collaborative Research program for the last 10  years .He  is  currently  the Principal Investigator of a large NIH grant  (grant number IUDIA1069436-01) sponsored through University of Zimbabwe-University of California Clinical Trials Unit.  He  provides scientific leadership that promotes high quality research for the 4 affiliated networks of ACTG, IMPAACT, Microbicides and HPTN. The research unit employs 350 people and has a well established DAIDS certified  laboratory and pharmacy and 6 clinical research sites with on site labs and pharmacies.

His research interest is cervical cancer screening and treatment in low resource settings. He also conducts HIV prevention clinical trials in women with particular studies on microbicides and pre exposure prophylaxis. He is the current chair of GARDISIL Access Program that has seen introduction of small scale operational projects for HPV vaccinnation program introduction through AXIOS.